Home » Stocks » KLDO

Kaleido Biosciences, Inc. (KLDO)

Stock Price: $6.55 USD -0.08 (-1.21%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 232.83M
Revenue (ttm) 250,000
Net Income (ttm) -79.95M
Shares Out 35.55M
EPS (ttm) -2.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $6.55
Previous Close $6.63
Change ($) -0.08
Change (%) -1.21%
Day's Open 6.52
Day's Range 6.40 - 6.74
Day's Volume 104,120
52-Week Range 2.82 - 11.89

More Stats

Market Cap 232.83M
Enterprise Value 180.29M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 35.55M
Float 12.20M
EPS (basic) -2.57
EPS (diluted) -2.62
FCF / Share -2.22
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.75M
Short Ratio 5.81
Short % of Float 22.57%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 931.32
PB Ratio 4.83
Revenue 250,000
Operating Income -78.29M
Net Income -79.95M
Free Cash Flow -70.70M
Net Cash 52.54M
Net Cash / Share 1.48
Gross Margin 100.00%
Operating Margin -31,314.00%
Profit Margin -31,978.40%
FCF Margin -28,281.20%
ROA -49.68%
ROE -117.61%
ROIC -410.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

(102.29% upside)
Current: $6.55
Target: 13.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-86.66-60.68-27.03
Net Income-86.33-61.74-27.56
Shares Outstanding25.705.114.47
Earnings Per Share-3.36-12.09-6.17
Operating Cash Flow-75.80-46.32-22.50
Capital Expenditures-3.59-3.00-1.41
Free Cash Flow-79.38-49.32-23.90
Cash & Equivalents73.5378.2728.68
Total Debt20.3914.8314.81
Net Cash / Debt53.1463.4413.87
Book Value48.88-96.24-43.68
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kaleido Biosciences, Inc.
Country United States
Employees 91
CEO Daniel L. Menichella

Stock Information

Ticker Symbol KLDO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KLDO
IPO Date February 28, 2019


Kaleido Biosciences, a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.